Skip to main content
. 2024 Mar 8;68(4):e01344-23. doi: 10.1128/aac.01344-23

TABLE 2.

Summary of lenacapavir pharmacokinetic parameters in moderate hepatic impairment, severe renal impairment, and healthy matched control groups

Pharmacokinetic
parametera
Cmax
(ng/mL)
Tmax
(h)
AUClast
(h*ng/mL)
AUCinf
(h*ng/mL)
CL/Fb
(L/h)
Vz/Fb
(L)
t1/2b
(days)
Hepatic impairment
Moderate hepatic impairment (n = 10) 61.1
(21.0, 229)
6.00
(2.00, 48.0)
11,900
(4940, 29,200)
12,000
(4,990, 29,600)
25.0
(10.1, 60.2)
10,800
(4,060, 23,000)
12.6
(9.74, 17.1)
Normal hepatic function (n = 10) 23.4
(9.70, 55.2)
4.00
(4.00, 12.0)
7,590
(3,050, 20,500)
8,180
(3,150, 20,700)
36.6
(14.5, 95.3)
17,000
(6,970, 49,800)
13.1
(10.7, 17.0)
Moderate hepatic impairment/normal hepatic function; GMR (90% CI) 2.61
(1.51, 4.52)
NC 1.57
(1.01, 2.43)
1.47
(0.947, 2.27)
NC NC NC
Renal impairment
Severe renal impairment (n = 10) 51.5
(6.80, 427)
8.00
(4.00, 48.0)
11,500
(1,310, 62,400)
12,100
(1,430, 63,000)
24.8
(4.76, 210)
8,560
(1,690, 46,000)
9.73
(5.69, 16.6)
Normal renal function (n = 10) 19.7
(5.90, 34.4)
6.00
(4.00, 48.0)
6,050
(2,420, 12,300)
6,590
(2,660, 13,200)
45.5
(22.6, 113)
20,900
(10,000, 52,300)
13.3
(11.0, 17.0)
Severe renal impairment/normal renal function; GMR (90% CI) 2.62
(1.12, 6.14)
NC 1.89
(0.952, 3.77)
1.84
(0.936, 3.60)
NC NC NC
a

Pharmacokinetic parameters presented to three significant figures. AUCinf, AUClast, Cmax, CL/F, and Vz/F presented as geometric mean (minimum, maximum); Tmax (time to maximal concentration) and t1/2 (half-life) presented as median (minimum, maximum). AUCinf, area under the plasma concentration–time curve from time 0 to infinity; AUClast, area under the plasma concentration–time curve from time 0 to the last quantifiable plasma concentration; CI, confidence interval; CL/F, apparent oral clearance; Vz/F, apparent volume of distribution; Cmax, maximum concentration; GMR, geometric least-squares means ratio; NC, not calculated; t1/2, half-life; Tmax, time to maximum concentration.

b

Nonparametric comparisons of PK parameters between hepatic and renal function groups are presented in (Table S5).